As obesity drugs go oral and access grows, so do fakes

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Weight-loss pills are reshaping the market, but easier access brings new risks for patients and the industry.

GLP-1 drugs have become the defining product class of the modern metabolic boom: weekly injections that can drive meaningful weight loss and improve glycemic control. Novo Nordisk and Eli Lilly turned them into household names, and the results have been impressive: studies show patients losing anywhere from 14% to 20% of their body weight over 72 weeks [1].

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3700

Wave Life Sciences

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Wave Life Sciences is a clinical-stage biotechnology company headquartered in Lexington, Massachusetts, focused on developing transformational RNA medicines across multiple modalities including RNA editing, splicing, RNA interference, and antisense silencing. The company leverages its proprietary PRISM platform, which combines advanced oligonucleotide chemistry, sequence design, and delivery strategies to address genetic and acquired diseases spanning neurology, muscle disorders, liver disease, and metabolic conditions such as obesity. Wave's pipeline encompasses first- or best-in-class therapeutics targeting alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and other serious genetic conditions, with the overarching mission to unlock the therapeutic potential of RNA-targeting approaches to transform human health.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE